Weight-loss drugs could become a test case for AI

Two of the buzziest technology trends in health care — artificial intelligence and weight-loss drugs — appear to be converging as companies increasingly scope out the potential to capitalize on both.

Why it matters: Some companies tell Axios the explosive demand, outsized costs and wide range of potential of uses for GLP-1s — the category of drugs that includes diabetes drug Ozempic and its weight-loss counterpart Wegovy — make them the perfect test case for AI's potential.